Digital Look

Welcome to Digital Look++,
you are not logged in

Advanced Search | Company A-Z | Feedback

Faron Pharmaceuticals Oy (DI) (FARN)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

202.00p

Change Today:

0.000p
52 Week High: 265.00
52 Week Low: 92.50

Currency: UK Pounds
Shares Issued: 111.60m
Volume: 4,163

Market Cap: £225.44m

FARN Overview

We are a clinical stage biopharmaceutical company focused on building the future of immunotherapy by harnessing the power of the immune system in order to tackle cancer and inflammation. Since our founding in 2007, our goal has been to develop a diverse and unique pipeline rooted in high quality science and innovation. Faron is focused on mastering immune modulation by harnessing endothelial receptors to control and mediate immune responses.

1 Day Chart

6 Month Chart

More Faron Pharmaceuticals Oy (DI) charts

Digital Look Charts Sponsored by Barclays Stockbrokers

Financials

	Latest	F'cast
Div Yield	0.0%	0.0%
Div Cover	n/a	n/a
Op Mrgn	n/a	-230.2%
ROCE	n/a

	Latest	F'cast
P/E	n/a	n/a
PEG	n/a	n/a
Pr/Revenue	n/a	22.0
Pr/Book	n/a

	Latest	F'cast
Revenue	n/a	n/a
PBT	n/a	n/a
EPS	n/a	n/a
DPS	n/a	n/a

FARN Fundamentals

Year Ending	Revenue ( m)	Pre-tax ( m)	EPS	P/E	PEG	EPS Grth.	Div	Yield
31-Dec-20	n/a	(16.93)	(37.00)¢	n/a	n/a	n/a	n/a	0.0%
31-Dec-21	n/a	(21.18)	(42.00)¢	n/a	n/a	n/a	n/a	0.0%
31-Dec-22	n/a	(28.73)	(52.00)¢	n/a	n/a	n/a	n/a	0.0%
31-Dec-23	n/a	(30.94)	(48.00)¢	n/a	n/a	n/a	n/a	0.0%
31-Dec-24	n/a	(25.92)	(29.00)¢	n/a	n/a	n/a	n/a	0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

FARN Forecasts

Year Ending	Revenue (£m)	Pre-tax (£m)	EPS	P/E	PEG	EPS Grth.	Div	Yield
31-Dec-25	9.83	(22.64)	(12.64)p	n/a	n/a	n/a	n/a	0.0%
31-Dec-26	n/a	(30.35)	(23.56)p	n/a	n/a	n/a	n/a	0.0%
31-Dec-27	20.98	(16.04)	(20.20)p	n/a	n/a	n/a	n/a	0.0%

Faron Pharmaceuticals Oy (DI) forecasts

FARN Company Announcements

FDA Grants Orphan Drug Designation	03-Mar-2025	12:05	RNS
Notice of Annual General Meeting	28-Feb-2025	12:00	RNS
Positive EMA Opinion on Orphan Drug Designation	27-Feb-2025	07:30	RNS

More Faron Pharmaceuticals Oy (DI) farn company announcements

FARN ShareCast News

Faron enters financing arrangement with Heights ...	03-Apr-2025	ShareCast
Faron identifies final patient in BEXMAB phase t...	31-Jan-2025	ShareCast
Faron Pharmaceuticals reports regulatory progres...	02-Dec-2024	ShareCast

More Faron Pharmaceuticals Oy (DI) ShareCast news

Latest FARN Director Deals

No deals were found in the last 28 days.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 3: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 4: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 5: Forecast figures based on normalised accounts.

FARN Market Data

Currency	UK Pounds
Share Price	202.00p
Change Today	0.000p
% Change	0.00 %
52 Week High	265.00
52 Week Low	92.50
Volume	4,163
Shares Issued	111.60m
Market Cap	£225.44m